Navigation Links
NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock
Date:12/9/2009

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that on November 25, 2009, it closed its previously announced public offering of 6,800,000 shares of its common stock at $3.30 per share. Novavax received net proceeds from the sale of the shares, after underwriting discounts, commissions and estimated offering expenses, of approximately $21 million, which will be used for preclinical studies and clinical trials of VLP-based vaccines, internal research and development programs, working capital, capital expenditures and other general corporate purposes.

Piper Jaffray & Co. and Lazard Capital Markets LLC acted as joint book running managers. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission at http://www.sec.gov or from Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by calling 1-800-747-3924.

The shares were issued pursuant to a shelf registration statement that was declared effective by the Securities and Exchange Commission on December 11, 2006. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy Novavax's common stock, nor shall there be any sale of the common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state.

The underwriters' option to purchase additional shares to cover over-allotments expired on December 8, 2009.

Novavax engaged Global Hunter Securities LLC and Merriman Curhan Ford as financial advisors to the company.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: our ability to satisfy all required closing conditions if the option is exercised; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and other factors referenced herein. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SILVER SPRING, Md. , March 23, 2017 /PRNewswire-USNewswire/ ... approval to Bavencio (avelumab) for the treatment of adults ... Merkel cell carcinoma (MCC), including those who have not ... for metastatic MCC, a rare, aggressive form of skin ... the most common cancers, patients with a rare form ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, 2017 ... (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ... today announced that data from its successful Phase 2a ... focal treatment for localized prostate cancer, will be presented ... 32 nd Annual European Association of Urology in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... offering. ... global oxygen therapy devices market to grow at a CAGR of ... Oxygen Therapy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, an insurance ... Collins area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as ... worthy cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones ...
(Date:3/23/2017)... ... March 23, 2017 , ... Altec Products, Inc. , ... as their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution ... award recognizes The Resource Group for their outstanding relationship with Altec and their ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of ... Change and Your Health on VoiceAmerica, recently talked on her program about how she ... the occasion to remind listeners of an important distinction. World Water Day, Kleyne pointed ...
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):